# Thermo Fisher Scientific Inc. (TMO) stock news and updates

As of November 18, 2026. Source: https://www.clearthesis.ai/updates/TMO

## Our view on the Thermo Fisher Scientific Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/TMO

## Latest updates on Thermo Fisher Scientific Inc.

### New cell medium launched to speed up vaccine manufacturing

*November 18, 2026 · product · significance: notable · signal: positive*

The company launched its VaxEvo CD 293 Medium, a specialized liquid used to grow the human cells that produce adenovirus vaccines. By making this medium animal-free and chemically defined, the company helps drugmakers meet strict safety standards while making it easier to scale up from a lab setting to a full factory. This launch is a classic example of the company's razor-and-blade model. While high-end lab machines get the headlines, the recurring sales of specialized liquids and chemicals needed to run those machines provide a steady, high-margin stream of income that makes the business more predictable.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261118289303/en/Thermo-Fisher-Scientific-Launches-Gibco%E2%84%A2-VaxEvo%E2%84%A2-CD-293-Medium-to-Advance-Adenovirus-Vaccine-Production/)

### Semiconductor manufacturers install new high-end microscope systems

*November 10, 2026 · product · significance: notable · signal: positive*

Thermo Fisher has completed multiple installations of its Optis FIB-SEM, a high-end system that combines ion beams and electron microscopes to analyze semiconductor samples. As chips become smaller and more complex, manufacturers need these tools to find tiny defects and ensure their designs actually work before moving to full production. While the company is best known for healthcare and lab equipment, its role in the semiconductor supply chain is a key part of its business. These installations show that even as chipmakers face pressure to innovate faster, they are relying on Thermo Fisher's automated tools to handle the precise data needed for next-generation electronics.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261110693903/en/Thermo-Fisher-Scientific-Continues-Semiconductor-Lab-to-Fab-Innovation-with-Multiple-Installations-of-Optis%E2%84%A2-FIB-SEM/)

### Board authorizes 5 billion dollars for share buybacks

*November 6, 2026 · news · significance: notable · signal: positive*

Thermo Fisher’s board approved a plan to buy back up to 5 billion dollars of its own stock. This new authorization replaces a previous plan that had about 1 billion dollars left, effectively adding 4 billion dollars to its capacity for repurchases. A buyback is when a company uses its cash to buy its own shares from the market, which reduces the total number of shares and makes each remaining share own a larger piece of the business. This move signals that management is confident in its cash flow and believes the stock is a good place to put capital to work for owners.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261105742300/en/Thermo-Fisher-Scientific-Authorizes-5-Billion-of-Share-Repurchases/)

### New value-priced laboratory testing mixes launched

*November 5, 2026 · product · significance: minor · signal: neutral*

Thermo Fisher launched a new line of chemical mixes, called master mixes, used in quantitative PCR testing. This process is a standard way labs measure and analyze DNA for research and medical diagnostics. These new products are designed to be a cheaper option for laboratories that are trying to manage tight budgets without losing the accuracy of their results. While this is a routine product update, it shows how the company is defending its market share by offering options at different price points as some research customers spend more cautiously.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261105419100/en/Thermo-Fisher-Scientific-Introduces-Value-Priced-Thermo-Scientific%E2%84%A2-AmpSure%E2%84%A2-Universal-qPCR-Master-Mixes-Without-Compromising-Performance/)

### Argus Research set a $780 price target

*November 4, 2026 · analyst · significance: minor · signal: positive*

Argus Research kept its buy rating on the company and set a price target of $780. This is notably higher than the average analyst target of $694 and suggests the firm sees more room for the stock to rise than many of its peers. This follows a recent trend of analysts raising their expectations after the company showed it could grow earnings even while some customers were spending less. While a single target change is routine, it reflects growing confidence in the company's ability to gain market share as a one-stop shop for lab equipment.

Sources: [Argus Research](https://www.streetinsider.com/Analyst+Comments/Thermo+Fisher+Scientific+%28TMO%29+PT+Raised+to+%24780+at+Argus/27261812.html)

## Thermo Fisher Scientific Inc. earnings

In Q3 2026, reported on October 21, 2026, Thermo Fisher Scientific Inc. posted earnings of $6.68 per share against $6.40 expected, and revenue of $12.1 billion against $12.0 billion expected.

The next earnings report is expected on February 4, 2027. Analysts expect $7.12 per share. Revenue is expected around $12.8 billion.

What to watch: Whether organic revenue growth stays above 5 percent, which would confirm that the recent rebound in laboratory activity is a lasting trend rather than a one-time pop.

## Recent analyst activity on TMO

- October 30, 2026: Argus Research Kept rating at Buy, set target. Price target: $780.00.
- October 23, 2026: Citigroup Kept rating at Buy, raised target from $685. Price target: $800.00.
- October 22, 2026: Baird Kept rating at Outperform.
- October 22, 2026: TD Cowen Kept rating at Buy, raised target from $760. Price target: $810.00.
- October 22, 2026: Barclays Kept rating at Overweight, raised target from $750. Price target: $775.00.
- October 22, 2026: RBC Capital Kept rating at Sector Perform, raised target from $580. Price target: $730.00.

## What's ahead for Thermo Fisher Scientific Inc.

- December 15, 2026: Dividend payday — Own the stock before this date to get the next dividend payment.
- February 4, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/TMO
